摘要
目的评价莫西沙星序贯治疗社区获得性肺炎（CAP）和慢性支气管炎急性加重期（AECB）等下呼吸道感染的疗效和安全性以及治疗费用。方法88例中、重度下呼吸道感染患者随机分为莫西沙星序贯治疗组（序贯组）和莫西沙星静脉滴注组（对照组），其中序贯组44例，于治疗当天开始，给予莫西沙星注射液400mg／250mI。静脉滴注，每日1次，3～5d后，换用莫西沙星片剂400mg口服，每日1次，总疗程7～10d；对照组44例给予莫西沙星注射液400mg／250mL静脉滴注，每日1次，总疗程7～10d。结果①序贯组和对照组痊愈率分别为65．9％（29／44）和68．2％（30／44），临床有效率分别为88．6%（39／44）和90．9％（40／44）；②细菌清除率分别为93．7％（30／32）和94．4％（34／36）。痊愈率和细菌清除率两组差异无统计学意义；③序贯组和对照组平均住院费用分别为（3658±456）元和（6825±387）元；序贯组和对照组平均住院日分别为（8．8±2．2）d和（13．7±1．5）d。两组间比较差异均有统计学意义；④不良反应发生率分别为序贯组11．4％（5／44）和对照组13．6％（6／44），均可耐受，无中途停药者，两组间差异无统计学意义。结论莫西沙星序贯治疗社区获得性呼吸道感染可以获得与莫西沙星全程静脉滴注给药相似的疗效，其不良反应少见，并且可以显著节省治疗费用，缩短住院时间，值得临床推广应用。
Objective To evaluate the efficacy, safety and cost of sequential moxifloxacin therapy in treatment of lower respiratory tract bacterial infections compared with moxifloxacin injection. Methods A total of 88 patients with lower respiratory tract infection were randomly enrolled into 2 groups： moxifloxacin injection group （control group） and moxifloxacin injection followed by tablet （sequential group）. Moxifloxacin was administered by intravenous infusion, 400 rag/250 mL once daily for 7-10 days in control group. In sequential group, moxifloxacin was given by intravenous infusion 400 mg/250 mL, once daily for 3-5 days, followed by oral administration at the same dose. The total treatment duration was also 7-10 days. Results The overall clinical efficacy rate and cure rate of sequential group were 88.6 %, 65.9 %, while the rates were 90.9 %, 68.2 % in control group. There was no significant difference （P〉0.05） between the tow groups. The bacterial eradication rate in the two groups was 93.7 M and 94.4% respectively. There was also no significant difference （P〉0.05） between the tow groups. The average in-hospital cost per patient was 3 658 ± 456 RMB Yuan in sequential group and 6 825 ± 387 RMB Yuan in control group. The average hospital stay was 8.8 ± 2.2 days in sequential group and 13.7 ± 1.5 days in control group. The difference was statistically significant. The incidence of adverse drug reaction in both groups was low. No serious adverse drug reaction was identified. The regimens were well-tolerated during this study. Couelusious The sequential moxifloxacin therapy for lower respiratory tract infections is safe, effective, and cost-effective compared with full-course moxifloxacin infusion.
出处
《中国感染与化疗杂志》
CAS
2007年第3期180-183,共4页
Chinese Journal of Infection and Chemotherapy
关键词
莫西沙星
序贯治疗
下呼吸道感染
社区获得性肺炎
慢性支气管炎急性加重期
Moxifloxacin
Sequential therapy
Lower respir- atory tract infection
Community acquired pneumonia
Acute exacerbation of chronic bronchitis
